KRAS and non-small cell lung carcinoma: The U.S. Food and Drug Administration granted expedited approval for sotorasib in the treatment of patients with KRAS G12C mutated non–small-cell lung cancer (NSCLC) who have undergone at least one prior systemic therapy (6).